inhibitor prolgolimab in metastatic skin melanoma: recent data and experience of use

1. Larkin J.M.G., Chiarion-Sileni V., Gonzalez R., Grob J.J., Rutkowski P., Laoet C. et al. 5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma ESMO, 2019. Annals of Oncology. 2019;30(5 Suppl.):v851–v934. https://doi.org/10.1093/annonc/mdz394.

2. McArthur G.A., Dréno B., Larkin J. 5-year survival update of cobimetinib plus vemurafenib BRAF V600 mutation-positive advanced melanoma: final analysis of the coBRIM study. Presented at: the 16th International Congress of the Society for Melanoma Research; November 20–23, 2019; Salt Lake City, UT.

3. Robert C., Grob J.J., Stroyakovskiy D., Karaszewska B., Hauschild A., Levchenko E. et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381(7):626–636. https://doi.org/10.1056/nejmoa1904059.

4. Tarhini A., McDermott D., Ambavane A., Gupte-Singh K., Aponte-Ribero V., Ritchings C. et al. Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. Immunotherapy. 2019;11(4):283–295. https://doi.org/10.2217/imt-2018-0168.

5. Puzanov I., Amaravadi R.K., McArthur G.A., Flaherty K.T., Chapman P.B., Sosman J.A. et al. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. Eur J Cancer. 2015;51(11):1435–1443. https://doi.org/10.1016/j.ejca.2015.04.010.

6. Schvartsman G., Taranto P., Glitza I.C., Agarwala S.S., Atkins M.B., Buzaid A.C. Management of metastatic cutaneous melanoma: updates in clinical practice. Ther Adv Med Oncol. 2019;11:1758835919851663. https://doi.org/10.1177/1758835919851663.

7. Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L. et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–2532. https://doi.org/10.1056/NEJMoa1503093.

8. Abramov M.E., Aliev M.D., Gafton G.I. Demidov L.V., Zhukova N.V., Novik A.V. et al. Melanoma of the skin and mucous membranes: clinical recommendations. Moscow; 2020.127 p. (In Russ.) Available at: https://melanoma.pro/uploads/docs/CR_melanoma_2020_final_compressed.pdf.

9. Frank G.A., Zavalishina L.E., Kekeyeva T.V., Aleksakhina S.N., Garifullina T.R., Ivantsov O.A. et al. First Russian nationwide molecular epidemiological study for melanoma: results of BRAF mutation analysis. Arkhiv Patologii = Archive of Pathology. 2014;76(3):65–73. (In Russ.) Available at: https://www.mediasphera.ru/issues/arkhiv-patologii/2014/3/1000419552014031065.

10. Ugurel S., Röhmel J., Ascierto P.A., Flaherty K.T., Grob J.J., Hauschild A. et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017;83:247–257. https://doi.org/10.1016/j.ejca.2017.06.028.

11. Schachter J., Ribas A., Long G.V., Arance A., Grob J.J., Mortier L. et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–1862. https://doi.org/10.1016/s0140-6736(17)31601-x.

12. Wolchok J.D., Chiarion-Sileni V., Gonzalez R., Rutkowski P., Grob J.J., Cowey C.L et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma N Engl J Med. 2017;377(14):1345–1356. https://doi.org/10.1056/nejmoa1709684.

13. Tjulandin S., Fedyanin M., Demidov L., Moiseyenko V., Protsenko S., Odintsova S. et al. Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimab in patients with advanced melanoma. Annals of Oncology. 2019;30(11 Suppl.):xi33–xi47. https://doi.org/10.1093/annonc/mdz451.

14. Robert C., Schachter J., Long G.V., Arance A., Grob J.-J., Mortier L. et al. Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma. Cancer Res. 2019;79(13 Suppl.). https://doi.org/10.1158/1538-7445.AM2019-CT188.

15. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Rutkowski P., Lao C.D. et al. ive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535–1546. https://doi.org/10.1056/nejmoa1910836.

16. Stroyakovskiy D.L. The effectiveness of the drug prolgolimab – what we need is it known? In: VI St. Petersburg International Oncological Forum "White Nights". St. Petersburg, June 25-28, 2020.

17. La J., Cheng D., Brophy M.T., Do N.V., Lee J.S.N., Tuck D., Fillmore N.R. RealWorld Outcomes for Patients Treated With Immune Checkpoint Inhibitors in the Veterans Affairs System. JCO Clin Cancer Inform. 2020;4:918–928. https://doi.org/10.1200/cci.20.00084.